RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30
RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and lowers the price target from $35 to $30.
An expert investor analyst still thinks Dyne Therapeutics is a good company, but she lowered her guess for what the stock price might be worth—from $35 down to $30. When experts lower their price targets, it often means they see some challenges ahead, even if they still believe in the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.